drug
Bortezomib Pfizer
Marketedupdated 6mo agoby Hospira Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and mantle cell lymphoma and 36 investigational indications.
all catalysts(1)
Trials studying Bortezomib Pfizer
- phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
- phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase3A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- phase2A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
- phase3A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 3, 2032
~6.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Sep 23, 2042method-of-use (U-3633)US 11679119
- Sep 23, 2042method-of-use (U-3633)US 11679119
- Sep 23, 2042method-of-use (U-3633)US 11752164
- Sep 23, 2042method-of-use (U-3633)US 11752164
- Sep 23, 2042formulationUS 12005069
- Sep 23, 2042formulationUS 12005069
- Nov 3, 2032formulationUS 8962572
News(1)
- Dr Chari on Frontline Combinations and Transplant Approaches in Multiple MyelomaAjai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that